TD
TD5A.F Tandem Diabetes Care Inc
- Market cap
- EUR 1.10B
- P/E
- -
- P/B
- 9.64x
- ROE
- -48.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is TD5A.F undervalued?
Graham numberThe Graham number of Tandem Diabetes Care Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tandem Diabetes Care Inc fundamental analysis
No fundamental analysis for Tandem Diabetes Care Inc yet.
Tandem Diabetes Care Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it …
Full company profileTandem Diabetes Care Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tandem Diabetes Care Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 84.2M | 108M | 184M | 362M | 499M | 703M | 801M | 748M | 940M | 1.01B | 1.05B |
| Gross Profit | 23.6M | 44.1M | 89.8M | 194M | 261M | 376M | 413M | 368M | 490M | 546M | 589M |
| Operating Income | -78.1M | -62.9M | -44.6M | -16.7M | -7.96M | 22.7M | -61.8M | -233M | -99.1M | -167M | -44.8M |
| EBITDA | - | -54.8M | -109M | -18.5M | -13.7M | 34.1M | -74.2M | -196M | -69.8M | -177M | -37.8M |
| Net Income | -83.4M | -73.0M | -123M | -24.8M | -34.4M | 15.6M | -94.6M | -223M | -96.0M | -205M | -64.9M |
| EPS | - | -7.22 | -2.13 | -0.42 | -0.55 | 0.24 | -1.47 | -3.40 | -1.45 | -3.00 | -0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 112M | 95.3M | 206M | 326M | 716M | 905M | 1.05B | 953M | 968M | 881M | 1.16B |
| Total Liabilities | 118M | 124M | 75.0M | 131M | 350M | 472M | 613M | 639M | 705M | 726M | 1.02B |
| Shareholders' Equity | -5.93M | -29.1M | 131M | 195M | 366M | 433M | 440M | 314M | 263M | 155M | 135M |
| Cash & Short-term Investments | 44.7M | 13.7M | 41.8M | 51.2M | 94.6M | 71.2M | 173M | 58.9M | 69.2M | 90.6M | 72.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -61.2M | -66.1M | -8.32M | 41.9M | 24.7M | 111M | 50.5M | -18.8M | 24.2M | -9.72M | -32.5M |
| Capital Expenditure | 8.93M | 5.72M | 2.99M | 19.5M | 27.4M | 14.2M | 34.1M | 29.7M | 19.2M | 98.5M | 20.0M |
| Free Cash Flow | - | -71.9M | -11.3M | 22.4M | -7.63M | 87.8M | 7.51M | -48.5M | 4.99M | -108M | -52.5M |
| Ratios | |||||||||||
| ROE | - | - | -93.4% | -12.7% | -9.4% | 3.6% | -21.5% | -71.0% | -36.5% | -131.9% | -48.0% |
| ROA | -74.2% | -76.6% | -59.4% | -7.6% | -4.8% | 1.7% | -9.0% | -23.4% | -9.9% | -23.2% | -5.6% |
| Net Profit Margin | -99.0% | -67.9% | -66.7% | -6.8% | -6.9% | 2.2% | -11.8% | -29.8% | -10.2% | -20.2% | -6.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Tandem Diabetes Care Inc dividends
Tandem Diabetes Care Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Oct 10, 2017.
Who owns Tandem Diabetes Care Inc
- Insiders 1.18%
- Institutions 98.82%
- Public & others 0.00%
- Shares outstanding 69.8M
- Free float 64.0M
Tandem Diabetes Care Inc company profile
- Company name
- Tandem Diabetes Care Inc
- Ticker
- TD5A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,500
- Fiscal year end
- December
- Address
- 12400 High Bluff Drive, San Diego, CA, United States, 92130
- Phone
- 858 366 6900
- Website
- tandemdiabetes.com
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Tandem Diabetes Care Inc management
9- Mr. John F. SheridanPresident, CEO & Director · born 1955
- Ms. Leigh A. VossellerExecutive VP, CFO & Treasurer · born 1973
- Ms. Shannon M. Hansen J.D.Executive VP, Chief Legal, Privacy & Compliance Officer and Secretary · born 1966
- Ms. Elizabeth Anne GasserExecutive VP and Chief Strategy & Product Officer · born 1976
- Mr. Jean-Claude E. KyrillosExecutive VP & COO · born 1964
- Mr. Rick A. CarpenterExecutive VP & CTO · born 1963
- Ms. Susan M. MorrisonExecutive VP & Chief Administrative Officer · born 1979
- Mr. Tom FoxExecutive VP & Chief Human Resources Officer
- Dr. Jordan Pinsker M.D.Chief Medical Officer